A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months

Trial Profile

A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Enterovirus A vaccine (Primary)
  • Indications Enterovirus A infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jan 2017 Primary endpoint of EV71-associated diseases has been met, according to results published in the Journal of Infectious Diseases.
    • 01 Jan 2017 Results published in the Journal of Infectious Diseases
    • 03 Jun 2013 Results published in the Lancet [online].
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top